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INTRODUCTION
All pharmacists working in clinical settings, whether dispensing 
medicines or advice, require a well-grounded knowledge of drug 
interactions (DIs) to prevent harm to patients from medicine 
combinations. This is an area, in which a pharmacist’s expertise a 
valued by other professionals and where a pharmacist’s knowledge 
of pharmacology can be recognized and appreciated. On the ongoing 
diagnostics, prevention, treatment in the different department of the 
hospital in the various types of the patient grouping in correspondence 
of the age, polypharmacy, gender, race, and hereditary, many DIs are 
been found. Those interactions are simple, usual, or the life threatening 
which may affect the loss of pharmacological action of the body and 
other activities of the body. The interaction of the drug is more evenly 
found in the cardiac department in prevalence with the cardiac disease; 
patient is more commonly found with the hypertension, ischemic heart 
disease, myocardial infarction, etc.
A drug-DI (DDI) may be defined as the pharmacological or clinical 
response to the administration of a drug combination which is different 
from that anticipated from the known effects of the two agents when 
given alone. The clinical result of a DDI may manifest as antagonism, 
synergism, or idiosyncratic.
DDIs are changed in drug’s effects caused by another drug taken 
during the same time period. Potential DIs (PDIs) may include, drug 
contraindications, drug combinations that require monitoring and 
possible dosage adjustment when given concomitantly. It is important 
not only to identify PDIs that are clinically meaningful but also to 
understand options to approach the potential loss efficacy or toxicity 
that may result when combinations of drugs are administered together.
PDI not only presents a danger to the patients but they can also 
greatly increase health-care costs. The outcome can be harmful if the 
interaction causes an increase in the toxicity of the drugs [1].
DDIs are changed in drug’s effects caused by another drug taken during 
the same time period [3].
Potential DDIs (PDDIs) may include, drug contraindications, drug 
combinations that require monitoring and possible dosage adjustment 
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 PDIs.  Our  study  is  more  PDIs  in  adult  patients.  Because  in  adults  lacking  of  nutrition’s  and  in  elderly  patients  multiple  prescribers, 
multiple drugs and multiple diseases. The number of potential drug-DI (PDDI) increased with an increase in the number of drugs prescribed. 
The numbers of drug prescribed increase with age. This DI has a potential to increase or decrease the therapeutic effect or to increase the risk of 
adverse drug reaction. An increased awareness of PDDIs, rational coprescription of drugs, and a close monitoring of patients in whom these 
drugs  are  prescribed  are  recommended.  The  recommendation  is  based  on  the  special  monitoring  and  the  perspiration  of  the  clinical 
pharmacist. The DI observed in the geriatric patient is more severe and common in compared to the other groups of study. The geriatric patient is 
physiological  disability  in  correspond  with  the  first-pass  metabolism  and  the  presence  of  the  other  diseases  which  also  enables  the  multiple 
prescriptions causing polypharmacy. The gender specification also the cause of the interaction, the female is more prone to the DI due to the hormonal 
distribution in the body and inability of the physiological function to absorb and the distribution. The special training should be provided to the 
pharmacist  for  looking  forward  of  the  geriatric  patient  and  female  patient.  The  training  regarding  the  prescription  their  adherence,  use, 
toxicity,  and  dosage  regimen  is  being  properly  enabled  in  the  training  for  the  practical  application.  This  study  helps  to  know  the  different 
interaction related to the cardiovascular agent with own class of the drug and the other class of drugs used therapeutically to care the disease.
ABSTRACT
In epidemiology, it is difficult to have an accurate estimate of
 the incidence of DIs mainly because published studies have 
frequently  used different  criteria  for  defining a  DI,  particularly  in 
distinguishing  between  clinically  significant  and  non-significant 
interactions.  Some  of  the  early  studies  uncritically  compared 
prescribed drugs with list of possible DIs without taking into 
account  their  potential  clinical  significance.  A  review  of  nine 
studies of the epidemiology of DDIs in hospital admissions found 
that  reported  incidence  ranged  from  0%  to  2.8%.  Out  of  nine 
studies, one study was like are DIs are important in clinical practice 
and have been estimated to account for 6–30% of all adverse drug
 reactions  (ADRs).  One  more  in  the  Harvard  Medical  Practice 
Study  of  adverse  events,  20%  in  acute  hospital  in-patients 
settings were drug related. Of these, 8% were considered to be due 
to DDIs [2].
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when given concomitantly. It is important not only to identify PDIs that 
are clinically meaningful but also to understand options to approach the 
potential loss efficacy or toxicity that may result when combinations of 
drugs are administered together [4].
In many cases, potentially interacting drugs can be given concurrently 
provided; the possibility of DIs is kept in mind and any necessary 
changes to dose or therapy are initiated promptly. However, concurrent 
use of potentially interacting drugs should be avoided altogether [4].
The clinical management of PDIs generally implies monitoring of 
symptoms related to a possible side effect and laboratory parameters 
such as serum-creatinine, internationalized ratio, and blood glucose, to 
prevent potentially serious adverse patient outcomes [5].
The most important step in avoiding adverse clinical consequences is 
knowledge of the potential toxicity of drug combinations so that a rational 
prescription can be made. For example, the clinician may administer the 
antibiotic if the interaction is unlikely to be important or can choose an 




The specific objectives of this study were as follows:
1. To assess the pattern of drug/drug class involved in these interactions
2. To assess the severity of DIs
3. To assess the onset of DI
4. To assess the outcome of the DIs.
5. To evaluate and assess the individual DIs.
METHODS
Study site
This study was conducted at Government General Hospital, Guntur. It 
is a 3000-bedded multispecialty/superspecialty tertiary care teaching 
hospital. This hospital provides primary and specialized health-care 
facilities to people in and around Guntur area. It is a major government-
owned multispecialty hospital in Guntur having the department 
such as cardiology, neurology, pediatrics, obstetrics, and gynecology. 
Approximately 1500–2000 patients are being treated every day. The 
patient is usually referred to this hospital by general practitioners.
Study design
This was a prospective and observational study.
Study period
The study period of 6 months was from October 2015 to March 2016.
Study criteria
Inclusion criteria




at least one are a cardiovascular agent.
Exclusion criteria






All the necessary data were collected from the important of all the four 






permanent damage may be induced. Normally, these drugs should 
not be administered together
2.	 Moderate	 interactions	 frequently	 cause	 therapeutic	difficulties,	
but the combination may be administered if the patient is carefully 
monitored (laboratory parameter, for example, quick value or clinical 
symptoms)
3. Minor interaction may cause increased or reduced effects or 
interactions only concerning a certain subgroup (for example, patient 
with renal or hepatic failure, slow acetylizers).
Criteria for onset
How rapidly the clinical effects of interactions can occur to determine 
the urgency with which preventive measure should be instituted to 
avoid the consequences of the interaction.
Two levels of onset are used
Rapid
The effect will be evident within 24 h of administration of the interacting 
drug. Immediate action is necessary to avoid the effects of interactions.
Delayed
The effect will not be evident until the interacting drug is administered 
for a period of days or weeks. Immediate action is not required.
PDI not only presents a danger to the patients but they can
 also  greatly  increase  health-care  costs.  The  outcome  can  be 
harmful  if  the  interaction  causes  an  increase  in  the  toxicity  of  the 
drugs [6].
Prospective  study  on  PDIs  of  cardiovascular  agents  in  the 
department of cardiology in a tertiary care teaching hospital.
Study procedure
An  approval  from  the  Institutional  Ethical  Committee  of 
Government  General  Hospital,  Guntur,  was  obtained  before  the 
study.  All  patients  admitted  to  cardiology  wards  during  the  study 
period were screened for case of any anti-cardiology agent. Those
 who met the inclusion criteria were included for the study purpose 
enroll for the study. Follow was carried out till the day of discharge 
from the hospital.  After the patient was included in the study, 
the data including,  demographic data such as the age,  gender, 
medical  history,  reason  for  admission,  and  comorbidities;  clinical 
data  such  as  hematology  and  biochemistry;  and  therapeutic  data 
including dose, duration, frequency, route, time of administration, 
and concomitant medication were collected and documented in 
the  suitably  designed  data  collection  form  (Annexure  1);  probable  DIs 
were  identified  using  the  software  MICROMEDEX  and  the  standard 
textbooks  (Martindale,  Dipiro,  Herdindal,  and  Kodakinalde).  The 
potential outcome of the interaction was accessed based on
 literature patient interview and discussion with clinician. 
Those  interactions  which  were  assumed  to  have  happened  in  the 
patient  were  evaluated  for  various  parameters.  Nature  of  interaction 
were evaluated with regard to onset, severity, and documentation was 
evaluated.  Data  were  accessed  to  evaluate  the  individual  drugs  and 
drug class involved in interactions. Data on interaction of the 
individual  drugs were evaluated based on demographic  (age and 
gender)  and  characteristics  of  interaction  (onset  and  severity).  Data 
were evaluated using suitable statistical tools.
Criteria for evaluation criteria for severity
The potential severity of the interaction is important in assessing 
the risk versus benefits of therapeutic alternatives. With appropriate 
dosage adjustments or modification of the administration schedule. 
The negative effect of most interactions can be avoided.
1. Major interactions may be life threatening, or intoxication or 
3
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Criteria for frequency
Frequency of PDIs was calculated as the total number of potential DDIs 
per total number of patients.
Statistical analysis
Descriptive statistical analysis has been carried out in the present study. 
Results on continuous measurement are presented on mean ± standard 
deviation (min-max) and results on categorical measurements are 
presented in number, percentage, etc. Confidence interval (CI) has been 
computed to find the significant features. CI with lower limit >50% is 
associated with statistical significance. Student’s t-test has been used to 
find the continuous scale.
Statistical software
The statistical software, namely, SPSS 20 Ver. and Microsoft Excel and 
diagrams advance analysis with Chi-square test with 95% CI.
RESULTS
The DDI based on age group was found with ranging from the age of 
25 above. The highest frequency was in the age duration of 61–70 age 
group with prevalence of the 105 frequency with the percentage of 
31.9%.
The gender-based participation was studied well and the participation 
was differentiated based with the age group and their gender specific 
with male and female. A total of 329 interactions were found in along 
with the 173 prescriptions, in which the 89 DIs are found in male with 
high frequency in the age group of 51–60 having the frequency of DDI 
40. The interaction on the male group is found to be 240 having high 
frequency in the age group of 61–70 years having frequency 83.
The participation of male and female with total expression with the 
percentage was statistically calculated and presented with the tables 
and the graphs. The maximum frequency in male and female is found to 
be 240 and 89, respectively, with the percentage of 72.9% and 27.1%.
The main focus of the research is to determine the severity of 
interaction among the interactions. The major, moderate, and minor 
were evaluated with the frequency of 170, 158, and 1, respectively, 
having the percentage of 51.7%, 48.0%, and 0.03%, respectively.
The main focus of the research is to determine the onset of interaction 
among the interactions. The delayed, not specified, and rapid were 
evaluated with the frequency of 95, 215, and 19, respectively, having 
the percentage of 28.9%, 65.3%, and 5.8%, respectively.
This was evaluated with the corresponding excel sheet report and using 
the software.
MICROMEDEX
The atorvastatin calcium reacts with the interacting drugs azithromycin, 
clopidogrel, digoxin, fentanyl, and ranolazine with times of, respectively, 
3, 4, 1, 3, and 4 with a total of 15 interaction was found in this study.
The clopidogrel interacts with the interacting drug dabigatran 
etexilate mesylate, enoxaparin sodium, fondaparinux, heparin calcium, 
indomethacin, rivaroxaban, and torsemide with the number of, 
respectively, 1, 5, 2, 7, 1, 1, and 1 with a total of 18 interactions was 
found in this study.
 The	 insulin	 human	 isophane	 interacts	 with	 the	 interacting	 drug	
dextrose, levofloxacin, metformin, metoprolol tartrate, ramipril, and 
sitagliptin phosphate with the number of, respectively, 1, 1, 1, 4, 2, and 
1 with a total of 10 interaction was found in this study.
The aspirin interacts with the interacting drug atenolol, bisoprolol 
fumarate, carvedilol, cilostazol, clopidogrel, dabigatran etexilate 
mesylate, diclofenac, enoxaparin sodium, enoxaparin sodium, 
The distribution of gender among the study sample was done and 
the value of frequency among the age group of below 60 years is 163 
with total percentage bearing 49.55% having Chi-square=0.027 and 
p=0.192. The 95% CI of upper bond and lower bond is 0.197 and 0.906, 
respectively, and the age group of above 60 years having the frequency 
of 166 bearing 50.45%.
DISCUSSION
Clinical pharmacists get an opportunity to work in a team and utilize 
the professional skills, knowledge, and expertise for better patients 
care.
It is impossible to remember all DIs of potential clinically significance. 
Health-care staff should be the continually alert to the possible of DIs 
and take appropriate steps to minimize their occurrence.
This is an area in which a pharmacist’s expertise a valued by other 
professionals and where a pharmacist’s knowledge of pharmacology 
can be recognized and appreciated. On the ongoing diagnostics, 
prevention, treatment in the different department of the hospital in 
the various types of the patient grouping in correspondence of the 
age, polypharmacy, gender, race, and hereditary, many DIs are been 
found.
Those interactions are simple, usual, or the life threatening which may 
affect the loss of pharmacological action of the body and other activities 
of the body. The interaction of the drug is more evenly found in the 
cardiac department in prevalence with the cardiac disease, patient is 
more commonly found with the hypertension, ischemic heart disease, 
myocardial infarction, etc.
It would be worth assessing the incidence and patterns of DIs for 
antimicrobials among these patients. Very few studies have been 
reported in literature to study the nature of DIs specifically among 
cardiovascular agents. Such data can be helpful in understanding 
opportunities for improving drug use. Hence, this study is taken to 
understand the incidence and pattern of DIs to cardiovascular agent in 
the cardiovascular department.
In total of 173 prescriptions of the patient, the total number of 329 DI 
was found, in which the 240 interactions were found in male and 89 in 
the female bearing 72.90% and 27.10%, respectively.
Table 1: Drug interaction differentiated based on age group







Above 80 6 1.8
Total 329 100.0
fondaparinux  sodium,  furosemide,  heparin,  heparin  calcium, 
heparin  sodium,  human insulin,  insulin,  insulin  aspart,  insulin  human 
isophane,  lisinopril,  magnesium  hydroxide,  metoprolol  tartrate, 
nebivolol,  NPH,  perindopril  erbumine,  ramipril,  sodium 
bicarbonate,  spironolactone,  ticagrelor,  and  torsemide  with  the 
number of, respectively, 3, 3, 8, 1, 23, 1, 1, 11, 1, 2, 5, 11, 1, 19, 2, 1, 8, 
2, 6, 1, 9, 29, 1, 1, 1, 10, 1, 4, 30, and 3 with a total of 199 interactions 
was found in this study.
Age
As shown in Table 1, in the current study, the involvement of the patient 
was of various age groups, in which the maximum frequency was seen 
in the age group of 61–70 years having 105 interactions bearing the 
percentage of 31.9%. As in the other age groups, less interaction was 
found which are as 25–30, 31–40, 51–60, 71–80 are 4, 20, 37, 102, 55, 6 
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In the reference study, the adults are exposed to more single and 
multiple regimens than younger. Majority 9 (28.1%) of patients 
with PDIs are more in 51–60 years. More than one potential drug – 
laboratory interaction was present in majority 19 (50%) of patients. 
Similar findings are found in a study conducted by Hovastadivs BO, 
Astrand B, and Petresson G, which concluded multiple medications 
should be regarded as a risk in forms of PDIs and ADR in all age groups.
Gender
As per Tables 2 and 3 and also Figs. 2 and 3 represent the participation 
of different age group of the male and female with their corresponding 
age. The participation of male is high having frequency of 240 (72.9%) 
than female participation of frequency 89 (27.1%). The participation of 
male in the age group of 61–70 years is 83 and the female is 40 in the 
age group of 51–60 years.
Table 2: Drug interaction differentiated based on gender wise 
with age
Age group Gender Total
Female Male
25–30 0 4 4
31–40 9 11 20
41–50 3 34 37
51–60 40 62 102
61–70 22 83 105
71–80 10 45 55
Above 80 5 1 6
Total 89 240 329












Fig. 2: Drug interaction differentiated based on gender wise with age
Fig. 3: Drug interaction classified according to gender
Fig. 4: Drug interaction classified based on severity in the 
department of cardiology
Wards
In our study, the various ward patients were studied in the Government 
General Hospital, Guntur. The patient in the intensive care unit was 
prescribed with the multiple drugs and the age was above 50 years. 
The male patient was found more as compared to the female with the 
 Fig. 1: Drug interaction differentiated based on age group
bearing the percentage as respectively 1.2%, 6.1%, 11.2%, 31%, 16.7%, 
1.8%.
Johnelli, Kristina, Klarin, Inga, which states that there seems to be
 a strong relationship between number of dispensed drugs and
 PDIs,  especially  for  potentially  serious  DDIs,  which  has 
implications for the importance of trying to minimize the number 
of  drugs  prescribed  in  the  elderly,  it  was  also  found  that  the 
probability of  potentially  serious DDIs decreases with increasing age 
among the elderly and that elderly woman has a lower probability of 
potentially serious DDIs.
In Tables 3 and 4 and Figs. 3 and 4 showed that PDIs were categorized 
based on the gender. In that compared to 13 (40.6) females, 
males 19 (59.4%) were found to have more PDIs. Our study is 
more  PDIs  in  adult  and  patients.  Because,  in  adults  lacking  of 
nutrition’s and in elderly patients multiple prescribers, multiple
 drugs and multiple diseases. The study conducted by Hersh 
EV  states  that  particularly  important  that  involvement  of 
health-care professional audit on these interactions would prevent 
potentially  serious  and  life-threatening  interactions  of  the 
antibiotics.
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age group of specification 61–70 years and 51–60 years, respectively. 
The intensive critical care unit was also found with the different 
aspect depending on their disease and the instability of conscious. The 
prescription of the drugs was followed up and the male patient was 
found to be 72.9% followed by female patient 27.1%.
PDI
A DDI may be defined as the pharmacological or clinical response to 
the administration of a drug combination which is different from that 
anticipated from the known effects of the two agents when given alone. 
The clinical result of a DDI may manifest as antagonism, synergism, or 
idiosyncratic.
DDIs are changed in a drug’s effects caused by another drug taken during 
the same time period. PDIs may include, drug contraindications, drug 
combinations that require monitoring and possible dosage adjustment 
when given concomitantly. It is important not only to identify PDIs that 
are clinically meaningful but also to understand options to approach the 
potential loss efficacy or toxicity that may result when combinations of 
drugs are administered together.
PDI not only presents a danger to the patients but they can also 
greatly increase health-care costs. The outcome can be harmful if the 
interaction causes an increase in the toxicity of the drugs.
The age bearing 61–70 years of male (geriatric patient) and 51–
60 years of female (geriatric patient) have more interaction due to their 
physiological and the kinetics of the body with the gastrointestinal and 
the other factors. Female is more contraindicated to the drugs as the 
results also show that the lees age of female is interacted with the drugs 
than the male. The multiple prescriptions also indicate the potential 
interaction due to their multiple interaction of therapy. Furthermore, 
the multiple diseases are observed in the patient having the age group 
above than the 50 years.
Severity
The severity of interaction major, moderate, and minor is indicated 
with the use of standard software MICROMEDEX. The prevalence of 
the study of the interaction of severity is classified based on their 
priority of interaction. As shown in Table 4 and Fig. 4, the majority, 
moderate, and minor were found with the frequency of 170, 158, and 
1 bearing the percentage of 51.7%, 48%, and 0.3% in the total of 329 
prescriptions.
Onset
The onset of interaction delayed, not specified, and rapid is indicated 
with the use of standard software MICROMEDEX. The prevalence of the 
study of the interaction of onset is classified based on their priority of 
interaction. As shown in Table 5 and Fig. 5, the delayed, not specified, 
and rapid were found with the frequency of 95, 215, and 19 bearing the 
percentage of 28.9%, 65.3%, and 5.8% in the total of 329 prescriptions.
Outcome of DIs
A total of 173 prescriptions were analyzed. A total of 329 PDDIs were 
detected, which were graded according to severity as serious, significant, 
minor, and contraindicated (Medscape, 2013 and Micromedics).
The prescriptions of every alternate patient were evaluated for PDDIs 
using freely accessible web-based DI checkers of Medscape (Medscape, 




Not specified 215 65.3
Rapid 19 5.8
Total 329 100.0
Fig. 5: Drug interaction classified based on onset in the 
department of cardiology 
Index drug Interacting drug Total





















































Table 6: Individual drug–drug interactions
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interacts with the interacting drug dabigatran etexilate mesylate, 
enoxaparin sodium, fondaparinux, heparin calcium, indomethacin, 
rivaroxaban, and torsemide with the number of, respectively, 1, 5, 2, 7, 
1, 1, and 1 with a total of 18 interactions was found in this study. The 
insulin human isophane interacts with the interacting drug dextrose, 
levofloxacin, metformin, metoprolol tartrate, ramipril, and sitagliptin 
phosphate with the number of, respectively, 1, 1, 1, 4, 2, and 1 with a 
total of 10 interactions was found in this study. Similarly, the aspirin 
interacts with the interacting drug atenolol, bisoprolol fumarate, 
carvedilol, cilostazol, clopidogrel, dabigatran etexilate mesylate, 
diclofenac, enoxaparin sodium, enoxaparin sodium, fondaparinux 
sodium, furosemide, heparin, heparin calcium, heparin sodium, 
human insulin, insulin, insulin aspart, insulin human isophane, 
lisinopril, magnesium hydroxide, metoprolol tartrate, nebivolol, NPH, 
perindopril erbumine, ramipril, sodium bicarbonate, spironolactone, 
ticagrelor, and torsemide with the number of, respectively, 3, 3, 8, 1, 23, 
1, 1, 11, 1, 2, 5, 11, 1, 19, 2, 1, 8, 2, 6, 1, 9, 29, 1, 1, 1, 10, 1, 4, 30, and 3 
with a total of 199 interactions was found in this study. The severity of 
interaction among the interactions as major, moderate, and minor was 
evaluated with the frequency of 170, 158, and 1, respectively, having 
the percentage of 51.7%, 48.0%, and 0.03%, respectively. The onset of 
interaction among the interactions of delayed, not specified, and rapid 
was evaluated with the frequency of 95, 215, and 19, respectively, 
having the percentage of 28.9%, 65.3%, and 5.8%, respectively. This 
was evaluated with the corresponding excel sheet report and using the 
software MICROMEDEX.
Age group Frequency Percent Chi-square value p-value 95% confidence interval
Upper bond Lower bond
≤60	years 163 49.55 0.027 0.912 0.917 0.906
>60 years 166 50.45
Total 329 100
Chi-square value and p-value show that there is no statistically significant difference between the age groups in the study sample
2003) and current index of medical specialties (CIMS) (CIMS, 2012), 
the average number of drugs prescribed, average number of PDDIs 
per prescription, and age-wise distribution of PDDIs. Nearly one-third 
of PDDIs were either serious or clinically significant. Polypharmacy 
was frequent in the present study with >50% prescription consisting 
of	more	than	eight	drugs	and	only	6.29%	with	<5	drugs.	The	average	
number of drugs prescribed per prescription was 5.28. Polypharmacy 
was also observed in a study conducted in geriatric hospitalized patients 
at Nepal (Joshi et al.,	1997).	Polypharmacy	increases	risk	of	DDIs	(Linn	
et al., 2011) and ADRs (Satoskar et al., 2011) and, hence, should be 
avoided. An average of 7.3 PDDIs was detected per prescription in the 
present study. The risk of DDIs increases with an increase in number 
of drugs prescribed (Tripathi, 2010). Accordingly, the average number 
of potential DDIs per prescription increased from 1.2 in prescriptions 
with	<5	drugs	 to	16.33	 in	prescriptions	with	more	 than	seven	drugs.	
In the study, we came to know the age, polypharmacy, and presence of 
disease with gender specification play the role of PDI.
Individual DIs
The individual DI depends on the age, gender, and the concurrent use 
with the other medications. The different drugs have shown different 
number of interaction based on their class and their use with the 
reference of the disease. As in this study, the atorvastatin calcium 
reacts with the interacting drugs azithromycin, clopidogrel, digoxin, 
fentanyl, and ranolazine with times of, respectively, 3, 4, 1, 3, and 4 
with a total of 15 interactions was found. Furthermore, the clopidogrel 
a b
c d
Fig. 6: (a-d) Individual drug–drug interactions
Table 7: The distribution of gender among study sample
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CONCLUSION
DIs mean two or more drugs given at the same time may exert their 
effects independently or may interact. PDIs may include, drug 
contraindications, drug combinations that require monitoring and 
possible dosage adjustment when given concomitantly. It is important 
not only to identify PDIs that are clinically meaningful but also to 
understand options to approach the potential loss efficacy or toxicity 
that may result when combinations of drugs are administered together.
The number of PDDI increased with an increase in the number of drugs 
prescribed. The numbers of drug prescribed increase with age. This 
DI has a potential to increase or decrease the therapeutic effect or to 
increase the risk of ADR. An increased awareness of PDDIs, rational 
coprescription of drugs, and a close monitoring of patients in whom 
these drugs are prescribed are recommended. The recommendation 
is based on the special monitoring and the perspiration of the clinical 
pharmacist. The DI observed in the geriatric patient is more severe and 
common in compared to the other groups of study. The geriatric patient 
is physiological disability in correspond with the first-pass metabolism 
and the presence of the other diseases which also enables the multiple 
prescriptions causing polypharmacy. The polypharmacy shows the 
differential DI based on the drug specification and their therapeutic action 
monitoring. The polypharmacy increases the interaction so it should be 
minimized to certain extent and need to be prescribe only if necessary. 
The gender specification also the cause of the interaction, the female is 
more prone to the DI due to the hormonal distribution in the body and 
inability of the physiological function to absorb and the distribution. The 
special training should be provided to the pharmacist for looking forward 
of the geriatric patient and female patient. The training regarding the 
prescription their adherence, use, toxicity, and dosage regimen is being 
properly enabled in the training for the practical application. During 
the prescription of the medication for the each patient, the history, 
background, the past medication, past allergies, and interaction are being 
studied in correspond with the individual patient and the prescription 
is being followed up to decrease the DI. Furthermore, the drugs are 
being evaluated with the various diagnostic data and the observation 
of the patient demographically and the correlation is done according 
to the requirement. The change of dosage route, dosage regimen, dose, 
duration of administration, and combination therapy is being employed 
to minimize the interaction. This study helps to know the different 
interaction related to the cardiovascular agent with own class of the drug 
and the other class of drugs used therapeutically to care the disease.
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